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Cancer, the second-leading cause of death in North America, is a major public health problem in 
the United States. Typically chemotherapy has been given to cancer patients by vein. Recently, 
effective oral cancer drugs are gaining prominence. This trend toward oral chemotherapy has 
important economic implications: the Medicare system of the United States pays for all 
intravenous (IV) chemotherapy, but it covers only those oral drugs that have an equivalent IV 
formulation approved by the Food and Drug Administration (FDA). The majority of oral cancer 
drugs in the cancer pipeline do not have such an IV equivalent. There are two proposals before 
the United States Congress to expand the Medicare program to cover all oral cancer drugs. 
Gefitinib (Iressa; AstraZeneca) is one of the most interesting of the cohort of novel, targeted oral 
cancer drugs. Already approved in Japan, it is currently under review by the U.S. FDA. This 
drug has relatively modest efficacy and few side effects; but it is likely to be expensive. Because 
the sponsor is seeking approval for the treatment of lung cancer, with a large annual incidence, 
the economic implications of an FDA approval for gefitinib have raised considerable concern. 
According to a pilot study presented herein, an approval for gefitinib would cost slightly over 
$US71 million dollars in total for the Medicare population not already covered by a prescription 
drug plan. Also, gefitinib was found to be cost-effective when compared to supportive care for 
the third-line treatment of non-small cell lung cancer, as long as the sponsor prices the drug in a 











CHAPTER 1: INTRODUCTION AND SPECIFIC AIMS 
The recent emergence of effective oral chemotherapy (e.g. imatinib mesylate for chronic 
myelogenous leukemia) represents one of the most important trends in clinical oncology. 
Historically, most (85-90%) administrations of chemotherapy for cancer have been given by 
vein, i.e. intravenously. The proportion of new cancer drug approvals that are orally available, 
however, is growing. In the future, oral cancer drugs may comprise half of all new drug 
approvals (Figure 1). 
Four factors are driving this trend. First, approximately 90% of cancer patients prefer oral 
chemotherapy when given the choice of an equally efficacious intravenous (IV) agent. l , 2 Second, 
economic savings to patients and the health care system may be possible when time-consuming 
chemotherapy infusions are avoided. The few pharmacoeconomic comparisons between oral and 
IV agents that have been performed to date appear to confirm such resource savings.3 Third, the 
vast majority of anticancer drugs under development are targeted therapies that require stable 
drug levels for effective tumort growth inhibition.4 These constant drug levels are best achieved 
by either oral delivery or IV infusion pumps; but pumps are inconvenient, expensive, and 
associated with infectious and thromboembolic complications.5 Lastly, the chronic use of oral 
agents is consistent with the paradigmatic shift within oncology to treating cancer as a chronic 
disease. 5 
The widespread use of oral chemotherapy introduces a major challenge to the United 
States (U.S.) health care system. While the Medicare program currently pays for the 
administration of all IV chemotherapy for Medicare enrollees, the program only reimburses for 
t This manuscript follows standard American spelling rules. The author acknowledges that standard English 











six of the 23 (26%) approved oral cancer drugs (Table 1). The current reimbursement policy 
requires that the oral agent be either chemically equivalent to, or a prodrug of, an approved IV 
chemotherapy drug. For example, capecitabine (Xeloda; Roche, Nutley, NJ), which is fully 
reimbursed by Medicare, is a prodrug of 5-flourouracil (5-FU) that is converted within tumor 
cells to the active agent. Since these six agents comprise a minority of all oral antineoplastics, 
older cancer patients are increasingly required to pay for their cancer drugs, which in some 
instances can amount to over US$3,OOOt a month. 
Because of growing political pressure (and in light of the failure of the most recent 
Congress to pass a comprehensive Medicare prescription drug plan), attention is now shifting to 
a possible Medicare drug plan specifically to reimburse oral chemotherapy. The particular 
resolution under congressional review would provide US$2.8 billion in direct funding for 
Medicare reimbursement of all oral chemotherapeutic agents for a yet unspecified number of 
years.6 Congressional action has been stalled, in part, by insufficient information on the 
economic and clinical impact of such a resolution. Namely, there have been no studies performed 
to date evaluating patterns of oral chemotherapy use among Medicare recipients. Nor are there 
published economic models available to predict the cost to the health care system of the 
introduction of new oral cancer drugs. 
The specific aims of this work were (1) to review the economic issues surrounding oral 
chemotherapy in the Medicare popUlation; and (2) to construct an economic model capable 
of predicting the societal economic impact of a widely publicized oral cancer drug, gefitinib 
(Iressa, formerly ZD 1839; AstraZeneca, Wilmington, DE, USA), which is currently under 
review for approval by the Unites States Food and Drug Administration. This work is intended to 
t All currency values in this manuscript are given in US dollars. As of 8 February 2003, 1 US$ equaled 























CHAPTER 2: THE ROLE OF CHEMOTHERAPY IN ADDRESSING THE CANCER 
PROBLEM IN THE UNITED STATES 
The Cancer Problem 
Cancer is the second leading cause of death in the United States, currently representing 
one in four deaths. 7 In year 2002 alone, there were an estimated 1,284,900 cases of invasive 
cancer diagnosed in the United States and approximately 555,500 cancer-related deaths.8 In 
addition to these invasive cancer, there are more than a million non-invasive skin cancers and 
55,000 non-invasive breast cancers diagnosed each year in the United States. As mortality from 
heart disease, the number one killer, continues to decline in North America, cancer is estimated 
to become the leading cause of death by 2005.9 According to statistics form the American Cancer 
Society, approximately 1,500 Americans die each day of cancer. The lifetime probability of 
developing cancer for men and women is 43.4% and 38.3% for men and women, respectively.lo 
Cancer, therefore, is a major public health problem in the United States, affecting a very large 
number of people. 
This burden is shared disproportionately across the population. Racial minorities and the 
elderly have the highest incidence and mortality rates from cancer. For example, African 
Americans have the highest incidence rates for cancer among all racial and ethnic groups in the 
United States; the incidence rate of cancer is 60 percent higher in African Americans than in 
Hispanics and Asian/Pacific islanders and is more than twice as high as the rate for American 
Indians.s Mortality rates also differ among racial groups: the mortality rate from cancer in 
African Americans is 33% higher than in whites.s With the exception of female breast cancer and 
female lung cancer, the overall incidence and death rates for the most common cancers are 











The burden is also disproportionately heavy for older Americans. Americans 65 years 
and older shoulder more than half of all new cancer diagnoses.7 This translated into 
approximately 640,000 older Americans diagnosed with cancer in 2002.11 Age, in fact, is the 
most powerful driver of cancer incidence. The chance of developing invasive cancer in any 
organ, for example, is estimated to be approximately 8.3% for an Americans male from age 40 to 
59; this chance goes up sharply to 33.1 % for an American males from age 60_79. 10 This jump in 
cancer incidence with age is somewhat less impressive for women. Yet, it is still clear that the 
threat of cancer increases exponentially as people, and the population as a whole, age. 
The National Response 
The national focus and investment in cancer research in the United States dates back to 
December, 1971 when President Nixon signed the National Cancer Act and launched the 
nation's "War on Cancer." The mandate, as stated in the Act, was to "support basic research and 
the applications of the results of basic research, to reduce the incidence, mortality and morbidity 
from cancer." There was the implication by the supporters of the National Act Cancer that cancer 
could be conquered by 1976, the American bicentennial. 12 Even though most scientists and 
physicians thought this goal was umealistic, the success of the American Apollo space missions 
in the late 1960's inspired such national optimism and exuberance. 
The National Cancer Act gave the National Cancer Institute (NCI) a high degree of 
autonomy at the National Institutes of Health (NIH). The Director of the NCI and its National 
Cancer Advisory Board became Presidential appointments; special budgetary authority allowed 
the NCI to bypass the Public Health Services and the Office of Management and Budget and go 











and affiliated university research laboratories. The national cancer drug development program 
was forged. Cancer became unique among other areas medicine in the United Sates in that the 
government explicitly sought to discover, develop, and test pharmaceuticals. For other diseases, 
this function was left to the commercial pharmaceutical industry. 
Unfortunately, the enthusiasm surrounding the National Cancer Act did not yield quick 
cures. The year 1976 came and went, and cancer remained undefeated. I 3 The National Cancer 
Act became a popular target in the press: the implication was that the NCr was mismanaging its 
funds and failing to produce results.12 Indeed, it would be almost 20 years after waging the "War 
on Cancer" before both overall incidence and mortality from cancer began to fall. 12 There were 
dramatic instances when new cancer drugs transformed the treatment of a specific type of cancer, 
but these have generally been rare. Progress, instead, has come incrementally. From 1992-1998, 
for example, cancer incidence and mortality declined approximately 1.1 % per year. Today, 
slightly more than 50% of patients with invasive cancers are cured. Unfortunately, the prognosis 
for most patients with advanced-stage, inoperable cancer remains grim. For these patients with 
advanced disease, treatment depends on the ability of chemotherapy drugs to stabilize the 
malignancy and, hopefully, extend survival and improve quality of life. 
Chemotherapy 
The National Cancer Act may not have produced cures for most of the common cancers, 
but progress was made. Newly developed chemotherapy agents, and combinations of established 
drugs, effected cures for thousands of people with lymphomas, leukemias, and germ cell tumors 
(e.g. testicular cancer and choriocarcinoma). Chemotherapy also established higher cure rates 











From 1975 through 2002, the U.S. Food and Drug Administration (FDA) granted 132 
marketing approvals for cancer drugs for the treatment of over 100 difference kinds of cancers. 14 
The rate of development and approval for cancer drugs accelerated rapidly over this time (Figure 
2). For example, the FDA granted only 3 approvals during the period of 1981 through 1985, 
compared to 55 approvals from 1996 through 2000. It is too early to tell whether the rate of 
cancer drug approval in the U.S. can sustain this impressive trend. 
Chemotherapy works in principle by killing or inhibiting the growth of neoplastic 
(cancer) cells to a greater extent than normal cells. Most chemotherapy drugs now on the market 
work by damaging or interfering with the synthesis of deoxyribonucleic acid (DNA), thereby 
killing all rapidly dividing cells. Some of these rapidly dividing cells, e.g. hair follicles, are 
normal cells. Chemotherapy drugs have traditionally had a narrow therapeutic index, meaning 
that there is little room for error in the dosing of the chemotherapy drug. IS Too little of the drug 
will have a sub-therapeutic effect on the tumor; too much of the drug can produce intolerable 
toxicity or even death. This toxicity to normal tissues has been the major limiting factor in the 
development of new cancer drugs and has influenced the way cancer drugs are given. Because of 
the narrow therapeutic index of cytotoxic chemotherapy drugs, most have been developed for IV 
use in order to limit the variability of drug levels in the blood. 
The Future of Cancer Chemotherapy and Drug Development 
Cancer drugs classically enter into three sequential phases of development before they are 
approved, each representing a distinct set of goals and challenges. If the results from these 
clinical trials yield particularly promising results, the sponsor may choose to submit a new drug 











have witnessed a remarkable and unprecedented proliferation of cancer agents in development. 
At the end of2001, there were an estimated 1,345 cancer drugs under investigation, with 837 in 
the preclinical stage and 196,219, and 67 in clinical Phases I, II, and III, respectively (Figure 
3).16 According to the Pharmaceuticals Research and Manufacturer's Association, the total 
number of novel cancer agents in the pipeline has increased 87% since 1995.17 Almost half of 
biotechnology firms now concentrate primarily on novel treatments and diagnostic tools for 
cancer. Cancer drugs under development now exceed the total of the next two most represented 
therapeutic classes, anti-infectives and cardiovascular agents, combined. 16, 17 
Most of these cancer drugs are targeted against specific molecules on or inside cancer 
cells. Because these new "targeted agents" rely on more specific cell killing, their therapeutic 
indices are much higher. They also rely on constant inhibition of their molecular targets, 
rendering periodic intravenous dosing ineffective. The combination of higher therapeutic indices 
and the requirement for steady drug level creates and opportunity and need for cancer drugs that 
can be safely given by mouth. 
A recent example of such an orally available cancer drug is imatinib mesylate (Gleevec; 
Novartis, East Hanover, NJ, USA).18 Imatinib mesylate targets a protein on the surface of 
chronic myelogenous leukemia (CML) cells, the bcr-abl kinase, which is not present on normal 
cells. When given to patients with CML, this oral drug, given once a day, can induce durable 
remissions in patients who otherwise would have undoubtedly died of their disease, despite the 
best alternative chemotherapy drugS. 19 The drug has few side effects and has been taken by some 
patients for several years with minimal toxicity. Because no IV equivalent formulation exists for 
imatinib mesylate, Medicare, the insurance plan that covers most Americans aged 65 and over, 











month,20 is out of the range of affordability for many American seniors (Table 2). Medicare does, 
however, reimburse for more toxic and less effective drugs to treat CML. Increasing, seniors in 
the U.S. are being placed in the position of choosing between less effective and more toxic IV 
chemotherapy, which is paid for by Medicare, versus less toxic and more effective oral 











CHAPTER 3: CHEMOTHERPY AND THE UNITED STATES MEDICARE SYSTEM 
The rationale for focusing on the Medicare Population 
There are several reasons to focus on the Medicare system when examining the economic 
impact of the shift to oral chemotherapy. First, this system covers the medical expenses of 
American aged 65 and over; as detailed in Chapter 2, these older Americans have dramatically 
higher odds of requiring oral chemotherapy drugs. Of the 41.5 million Medicare beneficiaries 
today, approximately 8.3 million (20%) have at least one diagnosis of cancer. I I Second, while 
most younger working Americans carry prescription drug coverage, standard Medicare enrollees 
do not carry a prescription drug benefit when the drugs are given outside of a hospital. Almost all 
oral chemotherapy is designed to be administered at outside of the hospital and is therefore not 
eligible for Medicare coverage. Third, the public debate in the United States regarding a 
prescription drug plan for Medicare is heating up once again. The President of the United States, 
in his State of the Union Address on 28 January 2003, recently highlighted the need to improve 
access to prescription drugs for the Medicare population.21 Senator Bill Frist, a physician who 
recently became the Majority Leader of the U.S. Senate, has also focused attention on a 
Medicare drug plan.22 In a time of steep budgetary cutbacks in the United States, the passage of a 
Medicare drug plan depends on the availability of reliable cost estimates. 
Medicare Overview 
The Unites States Congress created Medicare in 1965. The program serves Americans 
who are aged 65 or over and those qualifying for disability at any age. The disabled must be 











million beneficiaries to the Medicare Program: these included 35 million elderly and five million 
disabled persons. The disabled therefore represented approximately 15% of Medicare enrollees. 
23,24 Since its inception, Medicare has evolved into a highly regulated system that has a complex 
system of price controls. In fact, over 110,000 pages of rules and regulations govern almost 
every dollar spent under Medicare.23 
Medicare has three parts: Medicare A, B, and C. Part A covers services at institutions, 
such as surgery and hospital stays; Part B covers outpatient services such as physician visits. Part 
C, a recent addition to Medicare in 1997 that is also called Medicare+Choice, gives seniors the 
option of securing more comprehensive serviced by joining a private heath plan. Approximately 
86% of elderly Medicare beneficiaries participate in Parts A and B; the remainder participate in 
Part c.23 For the most part, the cost to seniors to enroll into Medicare is nominal. Most Medicare 
beneficiaries have contributed sufficient payroll taxes, amounting to 40 quarters of employment, 
by the time they are 65, to entitle them to receive Medicare Part A benefits without additional 
cost. Most also choose to participate in Part B to receive coverage for physician services. Unlike 
Part A, Part B requires a monthly premium. At US$58.70 per month, however, this premium is 
affordable to most Americans.25 
Whereas over 90% of private health plans in the United States offer a prescription drug 
plan, traditional Medicare Parts A and B do not with a few exceptions. These exception include 
the following outpatient drugs: immunosuppressive agents for enrollees who have received organ 
transplants; erythropoiten for patients with renal disease on dialysis who have anemia; clotting 
factors for the treatment of hemophilia; and oral cancer drugs that have an intravenous 
equivalent, comprising the minority of marketed oral cancer drugs.26 Medicare Part C was 











Organizations (HMOs). While some aspects of standard Medicare are curtailed for those 
choosing Part C, such as physician choice, these private plans are typically more comprehensive, 
providing preventive care, doctors visits, hospitalizations, and prescription drug benefits. 
Approximately 5.6 million Americans have chosen to participate in Medicare Part C, 
representing a small minority of seniors. Therefore, the majority of Medicare enrollees still do 
not carry a drug benefit. 
Without a public intervention, it is likely that that the number of older American without 
a dug benefit will grow. Medicare Part C has run into problems. Many private plans are dropping 
out of the program because the payments to these HMO's by the government have fallen. When 
the plans drop their participation, former members must return to traditional Medicare. In 2002 
alone, the Centers for Medicare and Medicaid Services announced that 58 plans would withdraw 
or diminish services, affecting 536,000 seniors nationwide.27 Without structural reform, it is 
unlikely that Medicare will be able to stop this trend. Medicare Trustees have reported that 
Medicare itself is heading toward bankruptcy by 2030. These projections are fueled by the rate of 
health care inflation for seniors. According to the Congressional Budget Office (CBO), total drug 
spending for the Medicare Population is expected to grow from US$87 billion in 2002 to 
US$278 billion in 2012, representing an average annual rate of over 10% and totaling US$1.8 
trillion over the nine-year period,zs By 2030, the total number of beneficiaries will be nearly 
double at 77 million; and taxes and premiums paid into the program will be less than the 











Prescription Drugs in the Medicare Population 
Prescription drugs are an important component of the American health care system. From 
a financing perspective, however, drugs have historically comprised a relatively minor 
component of total health spending. In 1999, for example, prescription drugs accounted for 
approximately 8 percent of the total national health spending; but this proportion is expected to 
increase to 14 percent by 201O?O These increases in drug spending will be driven by the 
introduction of new drugs,31 aggressive marketing campaigns through advertising directed at 
consumers,32 and higher prices.33 
For seniors, prescription drugs playa more critical role in their health care than the 
population in general. In fact, the number of prescription drugs filled per American is more than 
three times as high for those aged 65 and older compared to those under age 65?4 Unfortunately, 
almost 4 in 10 (38%) Medicare beneficiaries had no drug coverage as of the Fall of 1999 (Figure 
4); disturbingly, the access to these benefits are unequal across the Medicare population and 
declining.28 The groups with the least drug coverage include those living in rural areas, the near-
poor, and the oldest-old,zs For example, in the Fall of 1999 50% of Medicare beneficiaries living 
in rural areas lacked prescription drug coverage compared to 34% of those living in urban area. 
Similarly, 45% of emollees 85 years and older lacked prescription drug coverage compared to 
35% of those ages 65-74. Because of volume discounting, those beneficiaries without a 
prescription drug plan pay the highest prices, estimated at 15% higher, for drugs when they 
purchase them at community phannacies.26, 35 
The major sources of prescription drug coverage for Medicare beneficiaries are eroding. 
For example, the prevalence of employee-sponsored plans, which provide benefits for 28% of 











200 employees offering prescription drug coverage to those over age 65 fell from 41 % in 1999 to 
34% in 2001. This trend was accompanied by an increase in the retirees' share of prescription 
drug costs secondary to reduced benefits.28 Further erosion of employer-based drug benefits is 
expected. 36 
The second largest source of prescription drug coverage for seniors, behind employee-
sponsored plans, are Medicare HMOs, or Medicare Plan C (Medicare+Choice) plans. These 
plans assisted 15% of all beneficiaries with prescription drugs in Fall of 1999 (Figure 4). In 
recent years, however, the proportion of all Medicare+Choice beneficiaries with drug coverage 
declined from 84% in 1999 to 71 % in 2002; and 69% of all Medicare+Choice enrollees are 
subject to limits on drug benefits.37 
Other sources of funding for prescription drugs in the Medicare population, such as 
Medigap, are also threatened. Medigap is a program that allows Medicare enrollees to 
individually purchase supplemental insurance that provides limited prescription drug benefits. 
Because of adverse selection, these premiums tend to be quite high.36 For example, the average 
out-of-pocket drug cost in 1999 for an individual that purchased a Medigap policy was US$570. 
Perhaps because of these high premiums, the number of Medicare enrollees who purchased a 
Medigap policy has been declining rapidly over the past five years.27 Efforts by individual 
American state represent one of the few areas of growth of funding for the funding of 
prescription drugs in the elderly. As of September 2002,34 states had either established or 
authorized pharmacy assistance programs for seniors.28 These programs, however, vary widely 
with respect to what is covered and are too heterogeneous to represent a structural solution. Also, 











Out-oj-pocket Expenditure on Prescription Drugs Jor the Medicare Population 
The average annual per capita drug spending for the Medicare population in growing 
briskly. According to the Congressional Budget Office, the current annual spending is estimated 
at US$2,149 in 2002, a number which is increasing at an annual rate of 13%. According to the 
Centers for Medicare and Medicaid Services (CMS) [formerly the Health Care Financing 
Administration (HCFA)], this rate of increase is approximately twice that of total health care 
expenditures.3o The amount of drug spending is quite variable across the Medicare population; 
this skewing is shown in Figure 5. Approximately one-third of the population will incur less than 
US$501 in total expenditures in 2002, while fourteen percent of the population with exceeds 
US$4,000 in annual drug expenses. 
The skewness toward high out-of-pocket expenditure on drugs for seniors is one of the 
most compelling reasons to have insurance, even more so that average expenditure. For example, 
the average U.S. per capita spending on prescription drugs in 1999 was only US$358; this 
compared to US$413 for alcohol, tobacco, and entertainment. However, among elderly 
Americans, the top 4 percent of the heaviest users made up 24 percent of total drug spending for 
the elderly in 1996, while the bottom 40 percent only accounted for only 5 percent of spending.38 
While median per capita drug spending for the elderly in 1998 was only US$895, per capita 
spending for the 95th percentile was an alarming US$4,111.39 These data demonstrate that older 
American who are ill, and who happen to not have a prescription drug plan, may pay enormous 











CHAPTER 4: THE ECONOMICS OF CANCER CARE IN THE UNITED STATES 
The Cost of Cancer Care in the United States Health Care System 
The United States expends enormous resources to pay for its health care system. The 
latest projections estimate that U.S. national health expenditures will reach US$2.8 trillion by 
2011. These projections represent a projected growth rate of7.3 percent during the period 2001-
2011, which is 2.5 percent per year faster than nominal gross domestic product (GDP). If these 
projections play out, health spending in the United States will comprise 17 percent of GDP in 
2011, up from 13.2 percent in 2000.40 
The proportion of total health care expenditures spent on cancer care is growing. Cancer-
related costs rose approximately 10% per year from the late 1980s through the early 1990s and 
rose approximately 16% from 1995 to 1998. In 1999, the National Institutes of Health (NIH) 
estimated that total annual costs of cancer exceeded US$1 07 billion, with direct medical costs 
accounting for US$37 billion of the tota1. 41 The acceleration of cancer-related costs appears to be 
gaining pace. For example, a report from the National Cancer Institute revealed that cancer costs 
rose 62% over the five-year period from 1985 to 1990;42 In 2001, the NIH estimated the overall 
costs for cancer at US$157 billion, a jump of 47% over the period of just two years.11 
Expenditure on the most common cancers are responsible the bulk of these increases: the 
American Cancer Society estimates, for example, that breast, lung, and prostate cancer alone 
account for half of these direct medical costS.43 
Drivers of the Increases in Cancer Care Costs in the United States 
The are several forces driving the impressive cost increases in cancer care. First, cancer 











example, now detect cancers at earlier stages and allow patients to be treated who otherwise 
would have died of advanced cancer with little or no treatment at all. Dramatic improvements in 
supportive care make it feasible for most patients today, even the advanced elderly, to receive 
C; h' di 44 45 treatment .Lor t err sease. ' 
Whereas primary care physicians would routinely tell older patients with cancer that 
"nothing can be done," these patients are now referred to oncologists and receive life sustaining 
and life-improving treatments. Newer generations of chemotherapy agents developed over the 
last 10 years have incrementally, but significantly improved the experience of the majority of 
patients under treatments. Recently, novel drugs have been approved that provide excellent 
treatments for some diseases where no treatment previously existed. In the case of 
gastrointestinal stromal tumors (GIST), for example, a novel drug literally transformed the 
treatment of that disease.46 Many dying patients who received the agent, even those who were in 
hospice care, got better; some even were able to return to work. In other solid tumors, treatment 
advances have been less dramatic. Even in these cases, however, there have emerged a growing 
numbers of second- and third-line treatments that have proven efficacy for such diseases as lung 
and breast cancer. Many of these treatments were not available even 5-10 years ago. 
Another driver of cost increases that is often ignored is the substitution of newer, better 
treatments for older ones. These substitutions are often more expensive; but they must be taken 
in the context of their improved outcomes. When comparing costs of cancer care over the last 
10-15 years, it is important to consider that the experience of most cancer patients receiving 
treatment in the United States is substantially improved from their experience ten years ago. 
Newer drugs and radiation techniques have made the difference between patients spending 











are even working during treatment. The important trend toward a multidisciplinary approach to 
cancer care has undoubtedly increased cost but has also provided invaluable services to the most 
vulnerable patients. Newer, less toxic targeted therapies such as monoclonal antibodies and 
hormonal treatments are now routinely augmenting or substituting for more toxic cytotoxic 
chemotherapy, generally improving outcomes.47 
Even in the cancers where survival has increased only modestly, newer technologies and 
treatments have allowed patients to escape morbidity until much later in their disease course. 
This phenomenon, referred to by David Cutler and others as the compression of morbidity 
effect,48 is now routinely seen with treatment of many advanced cancers. In the treatment of 
metastatic lung cancer, for example, survival has increased only modestly over the past 10 
years.49 Quality oflife while on treatment, on the other hand, has increased substantially. Patients 
remain symptom free for longer and therefore have much less overall morbidity, limited in 
general to a short time at the end of life. 
The Costs of Chemotherapy in the United States 
Given the large increases in the cost of cancer care in the United States over the last 
several years, surprisingly little quantitative work has been published focusing on the dis-
aggregateed components of the total cost. The most complete study to date of outpatient 
chemotherapy expenditure was performed by Halbert, et aZ.41 This group studied the outpatient 
cancer costs in years 1995 and 1998 of a large cohort of patients enrolled in an HMO, including 
Medicare patients who chose to enroll in the HMO via the Medicare+Choice program. The group 
included patients from 20 American states who were diagnosed with cancer in either 1995 or 











A large portion ofthe cohort (88%) underwent treatment with chemotherapy at some 
point during the year. Total charges increased from US$1,218 per patient in 1995 to US$2,003 
per patient in 1998, an average annual increase of 18% per patient. This increase was shared 
equally by increases in professionally administered drugs, usually given intravenously; and in 
pharmacy claims, including oral chemotherapy and oral supportive medications. A closer look at 
these proportions reveals some interesting trends. Whereas the number of pharmacy claims 
increased by 9 percent from 1995 to 1998, the number of professional claims actually decreased 
by 5% annually. Therefore, charges per claim increased faster for professionally-administered 
drugs than for pharmacy claims. 
This study also allowed estimates of the various types of therapy on cancer-related drug 
charged. Chemotherapy contributed most (67%) to the total drug charges in 1998. Chemotherapy 
adjuncts, such as hematopoetic growth factor that allow chemotherapy to be given more safely, 
represented 18% of the charges. Supportive therapy, such as antibiotics and antidepressants, 
comprised 15% of the charges. In support of the assertion that oral chemotherapy is playing an 
increasingly important role in cancer care, the study reported that the proportion of the total 












CHAPTER 5: PREVIOUS WORK 
The Economics of Oral Cancer Drugs 
Despite the increasing prominence of oral chemotherapy, and the important resource 
implications introduced by the transition toward these agents, only a very few studies have been 
published that directly compare IV chemotherapy to oral chemotherapy in the treatment of a 
cancer.3, 50, 51 Moreover, there have been no published studies to date estimating the demand 
induced by the approval of a new oral cancer drug. The two most widely cited economic studies 
comparing an oral to an IV drug in oncology are presented below 
Oral Temozo10mide versus IV Dacarbazine in Advanced Metastatic Me1anoma5o 
Melanoma is a serious cancer that usually arises from pigmented cells in the skin. If it is 
recognized early, before it has the chance to invade vertically, surgical excision can provide an 
excellent chance for cure. If the cancer metastasizes to a lymph node, however, the chance for 
surgical cure decreases; and once the cancer metastasizes to a distant organ, the chance for cure 
is lost. Chemotherapy can palliate symptoms, and may even extend life, but these benefits are 
modest. Despite the considerable attention captured by biological therapies such as interferon 
and interleukin II, no drug has been shown to be consistently superior to IV dacarbazine.52 
Unfortunately, treatment of metastatic melanoma with dacarbazine is associated with a median 
survival of only 4-6 months. The drug also causes nausea and vomiting, and requires daily visits 
to a doctor's office or hospital for five days in a row every 3 weeks. Obviously, this therapy is 
sub-optimal for most patients with advanced melanoma, providing a compelling rationale to 











Temozo10mide (TEM) is a newer agent that, unlike dacarbazine, is taken by mouth; it is, 
however, metabolized to the same active metabolite as dacarbazine. The FDA granted marketing 
approval to TEM in 1999 for the treatment of anaplastic astrocytoma, a type of brain cancer. The 
FDA has not, to date, approved it for the treatment of melanoma. In the late 1990s, TEM's 
sponsor, Shering, initiated a randomized Phase III trial comparing IV dacarbazine to oral TEM in 
previously-untreated metastatic melanoma. 53 TEM was administered orally once a day for 5 
days, repeated every 28 days; dacarbazine was administered IV once a day for 5 days, repeated 
every 21 days. Treatment was continued to either unacceptable toxicity arose or until the cancer 
progressed. With 305 patients emolled, the trial had an 80% power to detect a 3-month 
prolongation in survival between the two arms. The tria1's major clinical finding was that the 
median progression-free survival was 1.9 months for TEM versus 1.5 months for DTIC (p = 
0.012, Hazard Ratio =1.37; 95% CI, 1.07 to 1.75). TEM therapy was also associated with higher 
health-related quality oflife (QOL) at 12 weeks on therapy. The percentage of patients whose 
tumor shrunk was similar between both arms. 
Because oral TEM is more expensive than IV dacarbazine, and marginally superior, if at 
all, Hillner, et al performed a post hoc economic analysis to illustrate pertinent trade-offs. 50 They 
chose incremental cost-effectiveness (CE) analysis as the primary assessment. They made the 
following key assumptions: (1) Patient survival and costs of palliative therapy after the 
development of progressive disease were assumed to be the same independent of the initial 
therapy and were therefore excluded. (2) Because maximum treatment was 1 year, and less than 
10% of patients were treated for 9 months, costs were not discounted. (3) Out-of-pocket costs 
and lost wages were not considered in the analysis, as they were assumed to be the same for the 











been biased because of the more frequent and earlier assessments in the IV dacarbazine arm 
(every 21 days) versus the TEM group (every 28 days) the lowered the HR from 1.37 to 1.18 for 
their assessment. 
In terms of resources and cost valuation, the authors identified and included in their 
model important resources used for patients in each arm ofthe trial, the number of units required 
per cycle, and each unit's baseline price and range. Drug costs were based on average wholesale 
prices in the United States, and also included a range for the sensitivity analyses. The cost of 
administering the IV chemotherapy was based on current reimbursements and not actual costs; 
the authors acknowledged that this approach may have underestimated the cost of administering 
the IV dacarbazine. Direct and indirect nonmedical costs, which recent guidelines have 
recommended including in CE analysis,54 were excluded from the base-case analysis because 
these costs were not collected during the trial. In their sensitivity analysis, they did include the 
cost ofUS$50 per half day per office visit for a family member; patients were assumed to not be 
able to work. 
The authors did not adjust survival in their model for QOL, because they argued that the 
completion rate for the health-related QOL questionnaires, at less than 66%, was too low to yield 
reliable estimates. At a 12-week assessment, patients on the TEM arm did indeed report 
significantly higher health-related QOL; therefore, again, the authors may have biased their 
results against the TEM arm. For their cost-effectiveness analysis, the authors calculated an 
incremental CE assessment: the additional cost of the TEM treatment for each added year of 
survival provided compared with the IV dacarbazine treatment.50 The base-case model was from 











authors did not show the structure of their model. While the use of hazard ratios might imply the 
use of a Markov model, they did not state this explicitly. 
The results of the base-case determined that the TEM treatment cohort had an average 
per-patient cost ofUS$6,902, compared with US$3,697 for the IV dacarbazine treatment, 
representing an increase ofUS$3,205 per patient. Assuming based on the trial data, that patients 
in the TEM group lived an average of 32 days longer, the incremental CE ratio was calculated at 
US$36,990. This value translated to US$lOl per extra day oflife-gained. Confidence intervals 
around the point estimate ranged from dacarbazine being dominant (when the survival of the 
dacarbazine group was assumed to be greater) to an incremental CE ratio for TEM ofUS$18,670 
per life-year gained. The authors performed a threshold analysis using the commonly employed 
threshold ofUS$50,000 per life-year gained: sixty percent (60%) of the simulations met this 
threshold. The authors therefore concluded that the incremental CE ratio of oral TEM in the 
treatment of metastatic melanoma was within the comparable range of many accepted medical 
interventions. Because Medicare pays for IV dacarbazine in the treatment of melanoma but does 
not pay for oral TEM--it is not FDA approved for treating melanoma--, the authors highlighted 
the tension confronting physicians they choose between similar agents that differ substantially in 
convenience and cost. 
Oral Capecitabine versus IV 5-fluorouracil C5-FU) in Advanced Colorectal Cancer 
Cancer of the colon and rectum (colorectal cancer) is a public health problem throughout 
the world. Globally, colorectal cancer is the third most commonly diagnosed cancer and the 











of people, and because its incidence is projected to rise with demographic shifts, the resources 
expended in its treatment will grow.3 
Like with melanoma, palliative treatments for advanced colorectal are sub-optimal. The 
standard treatment for advanced colorectal cancer has for years been based on the IV 
chemotherapy drug 5-fluorouracil (5-FU). This drug, which has a short half-life in the blood, is 
typically given in conjunction with another agent leucovorin (LV), which helps stabilize 5-FU to 
its target thereby increasing its ability to shrink tumors.56 Another approach is to administer 5-
FU with an infusion pump so that continuous drug levels are maintained. The response rates 
(percentage of patients who tumors shrank) associated with this approach have generally been 
higher, but infusion pumps are inconvenient, expensive, and prone to complications.57 Even with 
the best treatments available, including the recent addition ofirinotecan to 5-FU/LV, patients 
with metastatic disease tend to live less than 2 years, and cures are not possible. Thus, any 
innovations in treatment options that increase effectiveness or convenience are welcomed, 
particularly if they are cost-effective. 
One relatively recent innovation is the availability of an oral fluoropyrimidine drug that is 
formulated in pills and which gets converted to 5-FU in the tumor. This drug, capecitabine 
(Xeloda; Roche, Nutley, NJ, USA) was approved for the treatment of advanced colorectal cancer 
in 2001 based on a pivotal Phase III trial which showed higher response rates and equivalent 
survival when capecitabine was compared to IV 5-FU/LV. The 5-FU/LV treatment was given as 
an IV infusion at a clinic or hospital each day for 5 consecutive days every 4 weeks; capecitabine 
was given orally twice daily for 2 weeks followed by a week's rest. Treatment with either 
regimen was continued for 30 weeks or until the development of progressive disease or 











Because the IV 5-FU/LV and oral capecitabine displayed similar clinical efficacy, but 
had dramatically different administration schedules, the study prospectively collected resource 
use data at all participating centers on study case report forms. Information was collected on the 
number of scheduled visits made to a hospital, clinic, or office to receive therapy; the duration of 
the visits, the chemotherapy administered; number of unplanned consultations with general 
practitioners or specialist plus telephone consultations; hospital admission days; and treatments 
for the management of adverse events. The major findings of the study were (1) patient who 
received oral capecitabine required substantially fewer hospital visits, spent fewer days in the 
hospital for the management of adverse events, and required fewer expensive medications for the 
management of side-effects. (2) Because the patients administered the oral capecitabine at home, 
there were more unexpected phone consultations and more unscheduled clinic visits for the 
patients randomized to the capecitabine arm. Because these unscheduled clinic visits were 
deemed less resource-intensive compared to hospitalization, the authors concluded that 
capecitabine treatment of colorectal cancer results in substantial resource use saving relative to 
the IV 5-FU/L V. 
The study had three major limitations. First, the authors did not attach any cost estimates 
to the resource units that they identified and collected. For example, they did not quantify the 
cost of a scheduled clinic visit compared to an unanticipated hospitalization. This failure to 
attach cost estimates allowed only a qualitative conclusion, which is generally not as helpful for 
policy planning as a quantitative one. Second, the authors did not create a model based on their 
data to estimate whether the increased cost of the new oral drug capecitabine was offset by the 
resource use savings reported in the study. The failure to model the data also obviated the chance 











trial, which is an artificial and highly monitored setting. While this approach improves the 
reliability of the data, it does limit its generalizability. Patients entering clinical trials tend to be 
younger and healthier that the general cancer population; it is not clear that older, less well 
patients would have done as well with self-administered therapy where, by design, they are seen 
less frequently by a their physician. 
Knowledge Gap ill the Literature 
Both of these studies produce important insights into the economic implication of 
administering oral cancer chemotherapy as a substitute for an established IV equivalent. In both 
examples, the authors concluded that the oral cancer drug is either cost-effective or associated 
with less resource use. However, most oral cancer drugs in the pipeline are not direct substitutes 
for IV agents;59 most are completely novel agents that do not have an IV equivalent and which 
would not be paid for by standard Medicare. Also, since most of the novel, targeted oral drugs 
are less toxic than standard cytotoxic chemotherapy, the market for cancer drugs will likely 
expand, particularly among patients who have advanced disease and who are too sick to benefit 
from standard IV -based chemotherapy. To date, however, there have been no studies analyzing 
the economic impact of this expansion in demand. Therefore, the author set out to develop an 
economic model to estimate the economic impact of a novel, oral targeted therapy for advanced 











CHAPTER 6: A PILOT MODEL TO ESTIMATE THE COST AND EFFECTIVENESS 
OF A NOVEL ORAL CHEMOTHERAPY DRUG FOR THE 
TREATMENT OF NON-SMALL CELL LUNG CANCER 
The Questions 
The previous chapters and sections have described in some detail the very visible 
transition toward oral, targeted chemotherapy agents and away from IV cytotoxic ones. The 
previous chapters have also highlighted the challenges that accompany this transition, focusing 
in particular on the economic impact of oral chemotherapy to Medicare enrollees and to the 
Medicare system. These issues have come into sharp focus as the FDA reviews the controversial 
new drug application (NDA) of gefitinib (Iressa), an oral agent for the third-line treatment of 
non-small cell lung cancer (NSCLC). Approximately 85% of all lung cancer patients have this 
histologic sub-type of lung cancer. 
Gefitinib is a novel inhibitor of the epidermal growth factor receptor (EGFR), a growth-
promoting protein on the surface of cells. Particularly when compared to other treatments for 
lung cancer, gefitinib is relatively non-toxic: its major side effects include an acne-like rash on 
the face and chest and minor diarrhea. Because of its favorable toxicity profile, it can be given to 
lung cancer patients who would otherwise be too ill to receive standard cytotoxic chemotherapy. 
In Phase I and II clinical trials, gefitinib displayed modest activity against lung cancer, even 
when it was given to cancer patients who had received multiple previous chemotherapy drugs. 
Based on this modest activity, gefitinib's sponsor, AstraZeneca, submitted an NDA to the FDA 











previous lines of chemotherapy treatment or who were inappropriate for standard cytotoxic 
chemotherapy. 
Multiple pivotal clinical trials over the past 5-10 years have clearly established a 
palliative role for chemotherapy in good-functioning patients with advanced NSCLC (see Figure 
6). Based on these trials, the United States FDA has approved three first-line chemotherapy 
"doublet" treatments, each containing a platinum-based drug along with another newer 
chemotherapy agent. These two-drug combinations include the following: carboplatin plus 
paclitaxel, cisplatin plus docetaxel, and cisplatin and gemcitabine. None ofthe combinations has 
proven superior to any another.6o These drugs are typically given in 1 to 3-week intervals over 
the course of 12 to 18 weeks, followed by a period of rest. 
For those patients who maintain a good functional status, typically called perfOImance 
status (PS), and whose lung cancer progresses, the FDA has approved docetaxel, given alone, as 
a second-line chemotherapy. This agent is given once by vein every three weeks for 12 to 18 
weeks, followed again by rest. When the cancer progresses after docetaxel treatment, there are 
no FDA-approved third-line treatments for lung cancer. The treating oncologist can then decide 
whether to pursue a supportive care strategy alone or to prescribe an "off-label" chemotherapy 
agent, which means that the chemotherapy is approved for another cancer but not for the 
treatment of third-line lung cancer. These "off-label" treatments have, in general, a 10-20% 
chance of shrinking the tumor; one of the factors that discourage oncologists from pursuing "off-
label" prescribing is that patients typically display declining PS after two lines of chemotherapy 
and can therefore not tolerate standard chemotherapy. 
The FDA has announced plans to make a ruling on gefitinib's approval for the third-line 











for the same indication, and is before the European review regulatory boards as well. On 24 
September 2002, the FDA asked its Oncologic Drug Advisory Committee to vote on whether 
gefitinib's modest (10%) chance of shrinking tumors was meaningful in this disease; the 
committee voted 11 to 3 that it was. Despite this vote, the approval decision has been delayed in 
part to explore questions of potential pulmonary toxicity.61 There have been economic concerns 
as well. Unlike other industrialized countries, the U.S. FDA has no statutory role in evaluating 
cost-effectiveness when making their approval decisions; they are to base these decisions on 
safety and efficacy alone. There is, however, an undercurrent of concern that approving gefitinib 
for the treatment oflung cancer, which had an annual U.S. incidence of almost 170,000 in 2002,8 
would lead to inappropriate health care cost inflation for a drug with only modest activity. To 
date, however, there have been no published estimates of what the likely cost to the 
Medicare population would be of an approval for this drug. Nor have there been any 
published analysis of whether this treatment is likely to be cost-effective from a societal 
perspective when compared best supportive care in the third-line treatment of non-small 
cell lung cancer. The author's original pilot study, presented over the next several sections, will 
address these questions. 
Model Type Chosen 
A Markov, state-transition model was chosen as the underlying structure for this pilot 
study. Markov models are gaining increasing prominence in medical decision analysis. They are 
distinguished by their relative simplicity, explicit assumptions, ease of modeling prognosis data 
from clinical trials, and relatively faithful representation of many clinical and policy problems.62 











applied to economic question in most areas in oncology. Within the field of lung cancer, for 
example, they have been used to (1) analyze the cost-effectiveness of various staging strategies 
prior to cancer surgery64 and (2) determine if computed topography (CT) scanning is cost-
effective as a screening tool to detect early lung cancers.65 Considerable uncertainty surrounds 
both the costs and effectiveness of gefitinib; fortunately, Markov modeling provides the ability to 
perform rapid sensitivity analyses to test any underlying assumptions. This ability may be very 
useful in the planning for contingencies. 
The Clinical Trial Data Chosen for the Model 
There are no completed Phase III trials comparing gefitinib to best supportive care in the 
third-line treatment ofNSCLC. Therefore, it is unknown whether gefitinib extends survival in 
this setting. There have been, however, two large-scale open-label Phase II trials in patients with 
advanced NSCLC to evaluate the efficacy and tolerability of gefitinib in patients previously 
treated with platinum-based chemotherapy (see also Figure 6). One trial (IDEAL 1) was based 
mainly in Europe and Japan; the other (IDEAL 2) was based in the United States. These trials 
provided the basis for gefitinib's approval in Japan and provide the basis for pending new drug 
applications in the United States and Europe. The results have not been published in final form, 
but they have been presented in abstract form and have been reviewed e1sewhere.66 Because the 
author's home institution, the Massachusetts General Hospital, accrued a large number of 
patients to the IDEAL 2 trial, the author is intimately familiar with its design. 
The patients included in IDEAL 1 had a better prognosis because the entry criteria 
included patients who had failed one or two prior lines of chemotherapy. In order for patients to 











chemotherapy regimens. Therefore, from an U.S. perspective, IDEAL 2 applies more closely to 
the question at hand: Is gefitinib cost-effective for the third-line treatment ofNSCLC? The 
clinical data from IDEAL 2 were therefore chosen for use in the model. 
The IDEAL 2 trial was a randomized, double-blind Phase II trial investigating tumor 
response, disease-related symptom response, and safety of daily oral gefitinib (250 mg/day 
versus 500 mg/day) in advanced NSCLC. Of216 patients treated (median age 61 years-old), 102 
received 250 mg/day and 114 received 500 mg/day. Forty one percent (41 %) of the patients had 
failed 2 previous chemotherapy regimens; the remainder had failed more than 2 previous 
regImens. 
The proportion of patient who displayed objective tumor shrinkage on CT scans with 
treatment was approximately 10%; this proportion did not differ significantly between the two 
arms of the trial. The "response rate" of 10% is similar to what is seen with standard 
chemotherapy in heavily pre-treated patients. The proportion of patients reporting an 
improvement in their symptoms, such decreased amounts of shortness of breath or fatigue, was 
considerably higher at approximately 40%. The improvement in symptom relief came rapidly in 
most patients, as 60% of the patient reporting symptom did so by the second week of treatment. 
The median survival for both arms of the IDEAL 2 trial was approximately 6 months. The 
median number of months on therapy was 1.8 in IDEAL 2.66 Responses lasted up to 8 months. 
The patients who were randomized to the lower dose had fewer adverse events. As compared to 
historical trials of standard cytotoxic chemotherapy, these adverse events were generally mild 
and reversible; and few patients had to withdrawal from the trial because of drug-related adverse 
events. The sponsor of the IDEAL 2 trial, AstraZeneca, concluded from the data that gefitinib' 











alternative to best supportive care in those patients who have received prior approved 
chemotherapy. 
Constructing tlte Model for Third-Line Treatmellt of NSCLC Assuming Gifitinib's Approval 
The first step to building a Markov model is to enumerate all distinct health states. 62 
Classically, the three health states utilized in Markov models are WELL, ILL, and DEAD. As the 
model cycles through time, patients can transition between these health states as the model 
structure permits. These three states, however, often do not provide enough clinical nuance for 
the disease being modeled. In the case ofthe IDEAL 2 trial, there appeared to be 4 distinct 
potential health states: TAKING DRUGIRESPONDING, TAKING DRUGINOT 
RESPONDING, OFF DRUG/TERMINAL CARE, and DEAD. A schematic of these transition 
states, the allowable state transitions, and the accompanying Markov model of the IDEAL 2 trial 
are shown in Figure 7. This structure is the basis for modeling the effects of a possible FDA 
approval of gefitinib. 
In building the model of patient taking gefitinib for third-line treatment ofNSCLC, the 
following 6 assumptions were made. First, patient who were ultimately going to respond to 
treatment did so within the first month; the clinical data support this assumption as stated above. 
Second, once a patient is responding, they will continue to take the drug until there is evidence of 
disease progression; once disease progression is documented by physical exam or imaging test 
exam, they will enter the terminal care state. Once a patient enters terminal care, they will stay in 
that state, without receiving chemotherapy, until they die. Third, patients who do not show a 
response to the drug will continue taking it until their disease shows signs of progression or until 











patients who do not respond initially are likely to continue taking the drug in the hope that they 
will respond in the future, particularly since the side effects are minimal and since no additional 
treatment would be available after going off the drug. 
Forth, there are assumed to be no treatment-related deaths and no treatment-related 
morbidity. There have been reports of a 0.4% to 1.0% incidence of acute interstitial pneumonia 
with the use of gefitinib, accompanied by a 50% mortality rate when present;61 but lung cancer 
patients can develop acute interstitial pneumonia at similar rates without the use of gefitinib. 
Therefore, this is an area of some controversy, and the author acknowledges that the model may 
need to be adapted in the future to control for these reports. Fifth, patients taking gefitinib were 
assumed to have no survival over those not taking the drug. Until a Phase III randomized trial 
has been completed comparing gefitinib to supportive care, a survival advantage can not be 
assumed; and response rates alone have generally been a poor predictor of survival in 
oncology.67 Finally, it was assumed that all patients who lived long enough with advanced lung 
cancer to take gefitinib did so. This assumption is reasonable for those patients who could afford 
to pay for the drug. Few patients with advanced cancer would overlook a treatment with the hope 
of helping them if the side-effect profile was relative mild. 
Constructing the Model for Third-Line Treatment of NSCLC Assuming Gefitinib's Denial 
Under the assumption that the FDA does NOT approve gefitinib, there would be no 
FDA-approved treatment for patients who have failed a platinum-based and a docetaxel-based 
regimen. Therefore, assuming, somewhat simplistically, that there is no off-label chemotherapy 
prescribing, patients would only have two health states available to them: TERMINAL CARE 











FDA denial are shown in Figure 8. While the assumption of no "off label" prescribing may be 
umealistic for the general lung cancer population, it is probably more realistic for the Medicare 
population. It is a small minority (likely less than 25%) of elderly patients with advanced 
NSCLC who are well enough after receiving 2 regimens of chemotherapy to receive additional 
cytotoxic chemotherapy. 
Calculating the Hazard Ratios for State Transitions 
The state transitions for each health state in Figures 8 and 9 were modeled directly from 
the data in the IDEAL 2 trial. The survival and response times in IDEAL 2 were reported, like 
most trials, in median times. In order to model rates, these were converted to mean survival and 
response times. Survival time was modeled as an exponential function as below, which is a 
reasonable approximations for a severe disease like lung cancer.68. The derivation of this 
approach is presented in the sequence of equations as follows: 
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In both models, the Markov termination criteria were set at 24 months. This value was chosen, 
because patients with advanced NSCLC are very unlikely to live beyond this time, In order to 
illustrate the approach taken above, the state probabilities over time, under the assumption of 
FDA approval, are presented in Figure 9. 
Economic Evaluation and Resource and Cost Valuation 
As recommended by a recently-convened consensus panel, the viewpoint of this analysis 
is from the United States societal perspective; and the primary assessment was an incremental 
cost-effectiveness analysis.63, 69 The economic analysis was made simpler by the nature of the 
options under consideration. In both the supportive care only model (assuming the FDA denies 
marketing approval for gefitinib) and the gefitinib model (assuming the FDA approves gefitinib 
for third-line treatment oflung cancer), patients and accompanying family members are assumed 
to present to their treating physician for scheduled monthly visits. There was assumed to be no 
difference in resource utilization between those patients on supportive care compared to those 
patients on gefitinib, with the important exception of the cost of gefitinib. These are reasonable 
assumptions, since gefitinib does not require IV infusions; is not given with supportive 
medications; and has few side effects, which are relatively inexpensive to treat when they occur. 
It is also assumed that there are no differences in resource utilization between those patients who 
respond to gefitinib and those patients who do not. The decrease in tumor-related symptoms 
defined by responders may decrease resource utilization at the margin, but there effects are likely 
to be subtle and small when compared to the overall cost of caring for lung cancer patients at the 











likely to return to work, older patients with lung cancer, the popUlation being modeled, generally 
do not seek employment regardless of their response to therapy. 
Drug Costs, Cost of Supportive Care, Personal Costs, and Nonmedical Costs 
The cost of gefitinib has not yet been established in the marketplace in the United States. 
A base-case estimate ofUS$l,OOO per month oftherapy was chosen based on several factors. 
First, this price is in the conservative range of costs for other oral chemotherapy drugs (Table 2). 
While other oral chemotherapy drugs may have somewhat higher monthly costs, they are 
indicated to treat much rarer diseases; in those cases, the sponsor justifies higher prices claiming 
a tiny market size. There is intense political pressure in the current U.S. health care environment 
for drug companies adopt conservative pricing policies for new drugs, especially those drugs 
which treat life-threatening diseases like cancer and AIDS. The US$I,OOO per month is also in 
the range of the cost for "off-label" chemotherapy agents typically given for third-line treatment 
ofNSCLC. Finally, discussions with some representatives from gefitinib's sponsor confirmed 
that this value is in the range that is being considered should gefitinib obtain FDA approval. 
Fortunately, the Markov model allows for a broad range of pricing to be tested. For both the 
supportive care and the gefitinib models, it was assumed that no new capital or equipment costs 
would be incurred. 
The precise cost of providing supportive care for advanced-staged patients with NSCLC 
is unknown. Based on a previous analysis, this base-case cost was estimated to be on average 
US$I,800 per month.7o The monthly cost of patients treated with gefitinib was therefore modeled 
as the monthly cost of providing supportive care (US$I,800 in the base case) plus the monthly 











of best supportive care, the estimate of its cost will have a limited impact on the calculated 
incremental cost-effectiveness analysis. And again, the modeling allows for sensitivity analyses 
to be performed around these base-case estimates. 
Modeling Effectiveness of Therapv 
As detailed above, there was no survival advantage assumed for those patients receiving 
gefitinib compared to those patients receiving supportive care only. There was also assumed to 
be no quality of life difference between those patients on supportive care compared to those non-
responding patients taking gefitinib. Importantly, the model did control, however, for quality of 
life for those patients taking gefitinib who did respond to treatment. 
Utility states for the health states were obtained from published studies contained in a 
systematic overview of cost-utility assessments in oncology.7lThe utility, or QAL Y state, for 
patients with advanced NSCLC receiving supportive care or those taking gefitinib without a 
response were both assumed to be 0.69, based on previously-published study.72 Patients were 
assumed to stay in this health state until they died, which is a somewhat clinically unrealistic 
assumption. Due to better supportive treatments, however, the decline in utility at the end of life 
has been compressed to a relatively short time; particularly with hospice support, this assumption 
of non-declining utility it becoming more reasonable. 
The most difficult aspect of constructing the model was choosing an appropriate utility 
score for those patients who received gefitinib and enjoyed symptom relief. The quality of life 
and disease-related symptom relief were evaluated in IDEAL 2 with a common instrument in 
oncology called the Functional Assessment of Cancer Therapy for Lung Cancer (FACT -L, 











The FACT -L has proven to be reliable and comprehensive, yet brief and sensitive, means of 
assessing QOL domains in patients with lung cancer.73. 74 In particular, this instrument was 
validated by a large study conducted by the Eastern Oncology Cooperative Group.75 In the 
IDEAL 2 trial, approximately 40% of the patients who received gefitinib obtained an meaningful 
improvement in their FACL-L score that lasted at least four weeks; this improvement tended to 
occur within the first several week of treatment. Unfortunately, there has been no method to 
reliably convert from FACT-L scores to utility scores. Therefore, based on expert opinion of 
several thoracic oncologists and oncology nurses, as well as the author's own experience, a 
utility score of 0.80 was chosen for this group of "responders." The value 0.80 was chosen in 
particular because it has been published in a previous study to represent the utility state for 
patients with locally-advanced NSCLC,72 which is a stage oflung cancer just below metastatic 
lung cancer in its severity. Because patients with advanced lung cancer patients on average live 











CHAPTER 7: RESULTS AND POLICY IMPLICATIONS 
Base-case Analysis and Limited Sensitivity Analysis 
The Markov models were analyzed using commercially available modeling software 
(Data version 3.5 for Healthcare; TreeAge Software, Inc., Williamstown, MA, USA) were run 
using the base-case assumptions. The text report of the Markov analysis under the assumption of 
FDA-approval for gefitinib and FDA-denial of gefitinib are reported in Tables 3 and 4, 
respectively. These table were inspected in order to debug the model previous to its final run. As 
shown in these tables, the average cost of treating a patient with advanced lung cancer in the 
model with gefitinib was US$3,161; this cost was associated with an average effectiveness of 
0.51 QALYs. These values compared to an average cost ofUS$I,230 and average effectiveness 
of 0.45 QALYs to treat a patient with supportive care only in the third-line treatment setting. The 
incremental cost effectiveness ratio (leER) to treating with gefitinib therefore equaled: 
(US$3,160 - US$I,230)/ (0.51 QAL Ys 0.45 QALYs) US$32,183 per QALY. 
Extensive threshold and sensitivity analyses were beyond the scope of this pilot project; 
but limited sensitivity analysis did reveal some interesting trends. The leER of gefitinib was not 
particularly sensitive to the price for the drug. For example, even a doubling of the base-case 
estimate of gefitinib's cost to US$2,000 only increased the leER modestly, to US$35,516. The 
model was somewhat more sensitive to the utility state chosen for patients responding to 
gefitinib. A decrease in this estimate from 0.80 to 0.75, for example, increase the leER $38,620. 
The model provided leERs under $50,000 per QAL Y for the majority ofthe simulations run 












These pilot results have several limitations. First, the model is based on a highly 
controlled clinical trial, decreasing the ability to generalize the results. However, in a much-less 
controlled expanded access protocol of more than 250 patient treated at the Massachusetts 
General Hospital and Dana-Farber Cancer Institute in Boston, the clinical results were 
remarkably similar to IDEAL 2. Second, the pilot model made several assumptions that may not 
adequately describe the clinical nuance. The author is developing a more complicated model for 
eventual publication in order to capture this clinical nuance. Third, there will be "off-label" use 
of gefitinib, which Medicare can not easily identify. This model assumed that oncologist would 
prescribe gefitinib for its FDA-approved indication. Even within the context of these limitations, 
it is instructive to place the results in a larger societal perspective. 
The calculated base-case estimate of US$32, 183 per QAL Y is slightly less than US$l 00 
per day of quality-adjusted survival. Although league tables ranking the cost-effectiveness ratios 
of new therapies are fraught with limitations, the value of US$32, 183 is less than the commonly-
used standard of hemodialysis for end-stage renal disease. 50, 69 Because gefitinib has an ICER 
between US$20,000 and US$l 00,000 per year, its level would receive a "c" recommendation 
based on Canadian guidelines.76 
What are The Likely Costs to the Medicare System to Cover Patients Treated with Gifitinib? , 
From a Medicare systems standpoint, the critical question is how much would it cost to 
pay for all Medical enrollees with metastatic NSCLC to receive gefitinib for treatment after 
failing two previous regimens. Unlike other countries, the United States does not possess a 











The American Society publishes estimates the number of new cancers occurring annually in the 
United States by using age-specific cancer incidence rates form the NCI's Surveillance, 
Epidemiology, and End Results (SEER) Program, coupled with population data form the U.S. 
Census Bureau.7 The American Cancer Society then forecasts the number of cancer cases 
expected to be diagnosed in the United States in each year by using an autoregressive quadratic 
model.8 Using this approach, the total estimated new cases for lung cancer in 2002 was 169,400. 
The total estimated to have died of the disease was 154,900. For American patients, non-small 
cell lung cancer (NSCLC) is the dominant histology, responsible for 86% oflung cancers.77 
From a Medicare perspective it is important to point out that advancing age is associated 
with an increased incidence of lung cancer. Those patients over 70 comprise 51 % of the incident 
cases, which is a growing segment of the population.78 Approximately 40% of patients have 
advanced, incurable metastatic (stage IV) disease at the time of diagnosis. 79 By applying these 
estimates, the annual incidence of Medicare-eligible patients with advanced NSCLC who are not 
covered by an HMO drug plan can be calculates as follows: 
Annual incidence 169,400· N . Q . P . R . (1 S) 
N Percent ofNSCLC cases = 0.85 
Q Percent of incident cases aged?: 65 = 0.58 
P Proportion of patients presenting as Stage IV 0.40 
S Proportion of patients over 65 covered by HMOs 0.24 











It is also possible to use the published literature to estimate this number of Medicare-
eligible patients who would likely take gefitinib. Earle, et al examined the impact of referral 
patterns on the use of chemotherapy for cytotoxic lung cancer. 80 They studied patients from the 
11 tumor registries participating in SEER program. The SEER registries are estimated to capture 
97% of incident cases,81 covering approximately 10% of the American population.8 The 
coverage patterns are thought to be representative. 82 Ninety-four percent (94%) of the patients 
captured by SEER registries have been linked to the Medicare administrative database. 83 The 
Medicare database includes billing data for inpatient and outpatient care, physician and 
laboratory services, and home health and hospice care. 
This group examined all Medicare-eligible patients over age 65 who were diagnosed with 
stage IV (non-small cell lung cancer), the most common type oflung cancer, between 1 January 
1991 and 31 December 1996 (6-year period). Importantly, they excluded patients who had 
enrolled in a health maintenance organization (HMO), or those who had a previous cancer. 
Twelve thousand fifteen (12,015) patients met the eligibility criteria for the study. Sixty percent 
(60%) of the cohort were men, and the average age was 73.5 years. In order to get the annual 
incidence of lung cancer among Medicare-eligible patients using this data, the following 
calculations are required: 
Ann l ··d 12,015 1 1 ua mCl ence = .-.-
T U 6 
T = Percent of incident cases covered by SEER = 0.97 
U = Proportion of the population covered by SEER = 0.10 











This annual incidence of 20,644 is close to the estimate calculated from the American 
Cancer Society data. In the Earle study, 78% saw an oncologist at some time during the course of 
their disease; and twenty-six (26%) received chemotherapy at some point during their illness. 
This treated proportion increased from 24.9% in 1991 to 30.3% in 1996; this translated to an 
odds ratio to receive chemotherapy of 1.1 for each year of the study. 
Because not all patients receive treatment for their advanced NSCLC, these annual 
estimates represent the upper limit of Medicare patients not already covered by an HMO plan 
who would receive "on-label" use of gefitinib. Under the base-case assumptions, Medicare 
would be required to pay US$71,122,500 for the first year of a program to cover newly 
diagnosed older patients with advanced NSCLC to receive gefitinib. While the drug was shown 
in the previous section to be cost effective by the commonly-used standard ofUS$50,000, the 
aggregate cost of $US 71,122,500 is substantial. This value does not account for potential 
substitution effect ifpatients are treated "on-label" with gefitinib rather than "off-label" with IV 
cytotoxic chemotherapy. Most experts agree, however, that the approval of gefitinib would 
instead create an expansion effect of treatment for patients in the Medicare population because of 
its relatively non-toxic side-effect profile. 
Political Respsonse 
Several attempts to add outpatient drug coverage, including significant efforts by 
Presidents Clinton and Reagan, to the Medicare benefit package over the last 15 years have 
failed. 26 Within the field of oncology, the political efforts have shifted to lobbying Congress to 
allow Medicare to cover all oral cancer drugs. One such Congressional proposals, the Access to 











of all anti-cancer drugs, whether they be oral or injectable, for Medicare enrollees under Part B. 
The National Patient Advocate Foundation (NPAF) has been one the strongest supporters of this 
bill. 
According to the NP AF estimates, the overall costs of covering all oral anti-cancer drugs 
would add US$438 million to the Medicare budget in 2002 out of the US$78.5 billion that 
Medicare was expected to spend on cancer that year. The NP AF estimated that that according to 
the same (unpublished) analysis, the projected cost over five years is approximately US$2.8 
billion, or one half of one percent of Medicare's budget for cancer. I I Given that gefitinib is only 
one of many oral cancer drugs that Medicare would need to cover, and that it is likely to cost 
Medicare over US$70 million if approved and covered, this estimate of $438 million seems low. 
Concluding remarks 
To the authors' knowledge, this original work represents the most comprehensive 
analysis to date of the funding challenges introduced be the transition to oral cancer drugs. The 
author's economic model of gefitinib for the third-line treatment oflung cancer, although 
presented only in its pilot stage, illustrates that novel, oral targeted therapies are likely to be 
expensive, even if they are cost effective additions to the chemotherapy armamentarium. 
Because cancer is a disease of the elderly, and because the ability of the elderly to pay for 
prescription drugs is undeniably declining, the U.S. government should playa role in helping 
seniors to pay for life-sustaining and life-improving drugs. While seniors in the United States can 
exert tremendous political influence, it is uncertain whether geopolitical forces besetting the 
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Table 1. Approved Oral Anticancer Drugs in the United States which are Covered 





































Table 2. Average Monthly Cost Estimates for Selected Oral Cancer Drugs 
Drug 
chemical name (trade name) 
Capecitabine (Xeloda)t 













t Price of 240 capecitabine tablets (500 mg) = US$ 2,254.43. Schedule: 1,000 mg/m2 BID for 2 
weeks on therapy then 1 week off therapy; this is lower than the labeled dose, but most oncologists 
have adopted this schedule. Average BSA = 1.85. 
* Price of 120 imatinib mesylate tablets (100 mg) = US$2,362. Schedule: 400 mg QD. 
:t: Price of 20 temozolomide tablets (250 mg) = US$ 6,689. Schedule: 150 mgt m2 QD x 5 days of a 
28-day cycle. Average BSA = 1.85. 











Table 3. Model Output for Base-Case Analysis Assuming FDA-approval of 
Gefitinib 
DATA(tm) Markov Analysis 



























Shorthand state names: 
S 1 Responding 
S2 Not Responding 




























P(Sn) Probability of being in state n 



























r{Sn} Contribution to _stageJeward from state n 
- 59-
P(S1) P(S2) P(S3) P(S4) 
0.4 0.6 0 0 
0.2828 0.4242 0.293 0 
0.19994 0.29991 0.45825 0.0419 
0.14136 0.21204 0.53918 0.10743 
0.09994 0.14991 0.56562 0.18453 
0.07066 0.10599 0.55794 0.26542 
0.04995 0.07493 0.52991 0.3452 
0.03532 0.05298 0.49073 0.42098 
0.02497 0.03745 0.44642 0.49115 
0.01765 0.02648 0.40088 0.55499 
0.01248 0.01872 0.35648 0.61232 
0.00882 0.01324 0.31465 0.66329 
0.00624 0.00936 0.27612 0.70829 
0.00441 0.00662 0.2412 0.74777 
0.00312 0.00468 0.20994 0.78226 
0.0022 0.00331 0.1822 0.81229 
0.00156 0.00234 0.15776 0.83834 
0.0011 0.00165 0.13634 0.8609 
0.00078 0.00117 0.11765 0.8804 
0.00055 0.00083 0.1014 0.89722 
0.00039 0.00058 0.0873 0.91172 
0.00028 0.00041 0.0751 0.92421 
0.00019 0.00029 0.06457 0.93495 
0.00014 0.00021 0.05548 0.94418 
0.0001 0.00015 0.04764 0.95211 










Table 4. Model Output for Base-Case Analysis Assuming FDA-denial of 
Gefitinib 
DATA(tm) Markov Analysis 



























Shorthand state names: 
SI = Terminal Care 
























































































































Figure 1. Percentage of Approved Cancer Agents in the United States 







1953-1994 1995-2002 2003-2015* 
Source: Based on publicly available data on the oncology tools section of the FDA web site 
(http://www.fda.gov/cder/cancer/) 












Figure 2. Number of Unites States Oncology Drug Claims Approved by 5-year 
Intervals. 
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Source: Based on publicly available data on the oncology tools section of the FDA web site 
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Abbreviation: PS, Performance 














Figure 7. Health States, Allowable State Transitions, and Structure of Markov 
Model Under the Assumption of FDA APPROVAL of Gefitinib (Iressa). 
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Figure B. Health Allowable State Transitions, and Structure of Markov 
Model Under the Assumption of FDA DENIAL of Gefitinib (Iressa). 











Figure 9. Markov Probability Analysis under the Assumption of FDA Approval of 
Gefitinib 
lVlarkov Probability Analysis 
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